Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and β2-microglobulin, respectively
Identifieur interne : 001172 ( Main/Exploration ); précédent : 001171; suivant : 001173Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and β2-microglobulin, respectively
Auteurs : S. D. Lawn [États-Unis] ; D. Rudolph [États-Unis] ; S. Wiktor [Côte d'Ivoire] ; D. Coulibaly [Côte d'Ivoire] ; A. Ackah [Côte d'Ivoire] ; R. B. Lal [États-Unis]Source :
- Clinical and experimental immunology [ 0009-9104 ] ; 2000.
Descripteurs français
- KwdFr :
- Adulte, Antigènes CD (sang), Antituberculeux (usage thérapeutique), Femelle, Humains, Infections à VIH (immunologie), Infections à VIH (sang), Marqueurs biologiques, Mâle, Récepteur au facteur de nécrose tumorale de type I, Récepteurs aux facteurs de nécrose tumorale (sang), Tuberculose (immunologie), Tuberculose (sang), Tuberculose (traitement médicamenteux), bêta-2-Microglobuline (sang), Études transversales.
- MESH :
- immunologie : Infections à VIH, Tuberculose.
- sang : Antigènes CD, Infections à VIH, Récepteurs aux facteurs de nécrose tumorale, Tuberculose, bêta-2-Microglobuline.
- traitement médicamenteux : Tuberculose.
- usage thérapeutique : Antituberculeux.
- Pascal (Inist)
- Adulte, Femelle, Humains, Marqueurs biologiques, Mâle, Récepteur au facteur de nécrose tumorale de type I, Tuberculose, SIDA, Virus immunodéficience humaine, Marqueur biologique, Réponse immune, Facteur nécrose tumorale, Récepteur biologique, Microglobuline β2, Homme, Afrique Ouest, Études transversales.
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- AIDS, Adult, Antigens, CD (blood), Antitubercular Agents (therapeutic use), Biological marker, Biological receptor, Biomarkers, Cross-Sectional Studies, Female, HIV Infections (blood), HIV Infections (immunology), Human, Human immunodeficiency virus, Humans, Immune response, Male, Receptors, Tumor Necrosis Factor (blood), Receptors, Tumor Necrosis Factor, Type I, Tuberculosis, Tuberculosis (blood), Tuberculosis (drug therapy), Tuberculosis (immunology), Tumor necrosis factor, West Africa, beta 2-Microglobulin (blood), β2-Microglobulin.
- MESH :
- chemical , blood : Antigens, CD, Receptors, Tumor Necrosis Factor, beta 2-Microglobulin.
- chemical , therapeutic use : Antitubercular Agents.
- blood : HIV Infections, Tuberculosis.
- drug therapy : Tuberculosis.
- immunology : HIV Infections, Tuberculosis.
- Adult, Biomarkers, Cross-Sectional Studies, Female, Humans, Male, Receptors, Tumor Necrosis Factor, Type I.
Abstract
The aim of this study was to identify immune markers that are independently associated with HIV infection or TB in vivo. Using commercially available assays, we measured concentrations of five immune markers in sera from 175 out-patients attending medical clinics in Cote D'lvoire and Ghana, West Africa. Patients were categorized into groups with TB only (TB HIV, n = 55), TB and HIV coinfection (TB+ HIV+, n = 50), HIV infection only (TB HIV+, n = 35), or neither infection (TB HIV, n = 35). TBHIV+ and TB HIV+ groups were matched for blood CD4+ lymphocyte count. Mean ± s.d. concentrations of β2-microglobulin were similarly increased in both the TB HIV+ (5.3 ± 2.1 μg/ml, P < 0.001) and the TB +HIV+ (5.0 ± 1.5 μg/ml, P < 0.0001) groups compared with the TB HIV group (2.2 ± 1.8 μg/ml), but were only slightly increased in the TB+HIV group (3.2 ± 1.8 μg/ml, P = 0.01), In contrast, mean serum concentrations of soluble tumour necrosis factor receptor type I (sTNF-RI) were similarly elevated in the TB HIV (1873 ± 799 pg/ml, P < 0.0001) and TB+HIV+ (1797 ± 571 pg/ml, P < 0.0001) groups compared with uninfected subjects (906 ± 613 pg/ml), but there was only a small increase in sTNF-RI in the TB HIV+ group (1231 ± 165 pg/ml, P = 0.03). Both TB and HIV infection were associated with substantial elevation of serum concentrations of soluble CD8, soluble CD54, and sTNF-R type II. Analysis of additional samples from groups of TB +HIV and TB + HIV + patients receiving anti-TB treatment showed significant and equal reductions in mean serum sTNF-RI concentrations, but no significant change in mean β2-microglobulin. Thus, serum β2-microglobulin and sTNF-RI serve as relatively independent markers of HIV infection and TB, respectively, in studies of co-infected persons.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000141
- to stream PascalFrancis, to step Curation: 000008
- to stream PascalFrancis, to step Checkpoint: 000126
- to stream Main, to step Merge: 001253
- to stream Pmc, to step Corpus: 000320
- to stream Pmc, to step Curation: 000319
- to stream Pmc, to step Checkpoint: 000515
- to stream PubMed, to step Corpus: 000723
- to stream PubMed, to step Curation: 000723
- to stream PubMed, to step Checkpoint: 000723
- to stream Ncbi, to step Merge: 000031
- to stream Ncbi, to step Curation: 000031
- to stream Ncbi, to step Checkpoint: 000031
- to stream Main, to step Merge: 001212
- to stream Main, to step Curation: 001172
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and β<sub>2</sub>-microglobulin, respectively</title><author><name sortKey="Lawn, S D" sort="Lawn, S D" uniqKey="Lawn S" first="S. D." last="Lawn">S. D. Lawn</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and RetrovirologyBranch, Division of AIDS, STD, TB Laboratory Research, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Rudolph, D" sort="Rudolph, D" uniqKey="Rudolph D" first="D." last="Rudolph">D. Rudolph</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and RetrovirologyBranch, Division of AIDS, STD, TB Laboratory Research, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Wiktor, S" sort="Wiktor, S" uniqKey="Wiktor S" first="S." last="Wiktor">S. Wiktor</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Projet Retro-Cl and Centres Antituberculeux</s1><s2>Abidjan</s2><s3>CIV</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Côte d'Ivoire</country><wicri:noRegion>Projet Retro-Cl and Centres Antituberculeux</wicri:noRegion></affiliation></author><author><name sortKey="Coulibaly, D" sort="Coulibaly, D" uniqKey="Coulibaly D" first="D." last="Coulibaly">D. Coulibaly</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Projet Retro-Cl and Centres Antituberculeux</s1><s2>Abidjan</s2><s3>CIV</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Côte d'Ivoire</country><wicri:noRegion>Projet Retro-Cl and Centres Antituberculeux</wicri:noRegion></affiliation></author><author><name sortKey="Ackah, A" sort="Ackah, A" uniqKey="Ackah A" first="A." last="Ackah">A. Ackah</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Projet Retro-Cl and Centres Antituberculeux</s1><s2>Abidjan</s2><s3>CIV</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Côte d'Ivoire</country><wicri:noRegion>Projet Retro-Cl and Centres Antituberculeux</wicri:noRegion></affiliation></author><author><name sortKey="Lal, R B" sort="Lal, R B" uniqKey="Lal R" first="R. B." last="Lal">R. B. Lal</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and RetrovirologyBranch, Division of AIDS, STD, TB Laboratory Research, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">00-0517421</idno><date when="2000">2000</date><idno type="stanalyst">PASCAL 00-0517421 INIST</idno><idno type="RBID">Pascal:00-0517421</idno><idno type="wicri:Area/PascalFrancis/Corpus">000141</idno><idno type="wicri:Area/PascalFrancis/Curation">000008</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000126</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000126</idno><idno type="wicri:doubleKey">0009-9104:2000:Lawn S:tuberculosis:tb:and</idno><idno type="wicri:Area/Main/Merge">001253</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1905745</idno><idno type="RBID">PMC:1905745</idno><idno type="wicri:Area/Pmc/Corpus">000320</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000320</idno><idno type="wicri:Area/Pmc/Curation">000319</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000319</idno><idno type="wicri:Area/Pmc/Checkpoint">000515</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000515</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">000723</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000723</idno><idno type="wicri:Area/PubMed/Curation">000723</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000723</idno><idno type="wicri:Area/PubMed/Checkpoint">000723</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000723</idno><idno type="wicri:Area/Ncbi/Merge">000031</idno><idno type="wicri:Area/Ncbi/Curation">000031</idno><idno type="wicri:Area/Ncbi/Checkpoint">000031</idno><idno type="wicri:doubleKey">0009-9104:2000:Lawn S:tuberculosis:tb:and</idno><idno type="wicri:Area/Main/Merge">001212</idno><idno type="wicri:Area/Main/Curation">001172</idno><idno type="wicri:Area/Main/Exploration">001172</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and β<sub>2</sub>-microglobulin, respectively</title><author><name sortKey="Lawn, S D" sort="Lawn, S D" uniqKey="Lawn S" first="S. D." last="Lawn">S. D. Lawn</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and RetrovirologyBranch, Division of AIDS, STD, TB Laboratory Research, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Rudolph, D" sort="Rudolph, D" uniqKey="Rudolph D" first="D." last="Rudolph">D. Rudolph</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and RetrovirologyBranch, Division of AIDS, STD, TB Laboratory Research, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Wiktor, S" sort="Wiktor, S" uniqKey="Wiktor S" first="S." last="Wiktor">S. Wiktor</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Projet Retro-Cl and Centres Antituberculeux</s1><s2>Abidjan</s2><s3>CIV</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Côte d'Ivoire</country><wicri:noRegion>Projet Retro-Cl and Centres Antituberculeux</wicri:noRegion></affiliation></author><author><name sortKey="Coulibaly, D" sort="Coulibaly, D" uniqKey="Coulibaly D" first="D." last="Coulibaly">D. Coulibaly</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Projet Retro-Cl and Centres Antituberculeux</s1><s2>Abidjan</s2><s3>CIV</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Côte d'Ivoire</country><wicri:noRegion>Projet Retro-Cl and Centres Antituberculeux</wicri:noRegion></affiliation></author><author><name sortKey="Ackah, A" sort="Ackah, A" uniqKey="Ackah A" first="A." last="Ackah">A. Ackah</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Projet Retro-Cl and Centres Antituberculeux</s1><s2>Abidjan</s2><s3>CIV</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Côte d'Ivoire</country><wicri:noRegion>Projet Retro-Cl and Centres Antituberculeux</wicri:noRegion></affiliation></author><author><name sortKey="Lal, R B" sort="Lal, R B" uniqKey="Lal R" first="R. B." last="Lal">R. B. Lal</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>HIV and RetrovirologyBranch, Division of AIDS, STD, TB Laboratory Research, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Clinical and experimental immunology</title><title level="j" type="abbreviated">Clin. exp. immunol.</title><idno type="ISSN">0009-9104</idno><imprint><date when="2000">2000</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Clinical and experimental immunology</title><title level="j" type="abbreviated">Clin. exp. immunol.</title><idno type="ISSN">0009-9104</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Adult</term><term>Antigens, CD (blood)</term><term>Antitubercular Agents (therapeutic use)</term><term>Biological marker</term><term>Biological receptor</term><term>Biomarkers</term><term>Cross-Sectional Studies</term><term>Female</term><term>HIV Infections (blood)</term><term>HIV Infections (immunology)</term><term>Human</term><term>Human immunodeficiency virus</term><term>Humans</term><term>Immune response</term><term>Male</term><term>Receptors, Tumor Necrosis Factor (blood)</term><term>Receptors, Tumor Necrosis Factor, Type I</term><term>Tuberculosis</term><term>Tuberculosis (blood)</term><term>Tuberculosis (drug therapy)</term><term>Tuberculosis (immunology)</term><term>Tumor necrosis factor</term><term>West Africa</term><term>beta 2-Microglobulin (blood)</term><term>β2-Microglobulin</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Antigènes CD (sang)</term><term>Antituberculeux (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Infections à VIH (immunologie)</term><term>Infections à VIH (sang)</term><term>Marqueurs biologiques</term><term>Mâle</term><term>Récepteur au facteur de nécrose tumorale de type I</term><term>Récepteurs aux facteurs de nécrose tumorale (sang)</term><term>Tuberculose (immunologie)</term><term>Tuberculose (sang)</term><term>Tuberculose (traitement médicamenteux)</term><term>bêta-2-Microglobuline (sang)</term><term>Études transversales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antigens, CD</term><term>Receptors, Tumor Necrosis Factor</term><term>beta 2-Microglobulin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antitubercular Agents</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>HIV Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à VIH</term><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antigènes CD</term><term>Infections à VIH</term><term>Récepteurs aux facteurs de nécrose tumorale</term><term>Tuberculose</term><term>bêta-2-Microglobuline</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antituberculeux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Biomarkers</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Receptors, Tumor Necrosis Factor, Type I</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Adulte</term><term>Femelle</term><term>Humains</term><term>Marqueurs biologiques</term><term>Mâle</term><term>Récepteur au facteur de nécrose tumorale de type I</term><term>Tuberculose</term><term>SIDA</term><term>Virus immunodéficience humaine</term><term>Marqueur biologique</term><term>Réponse immune</term><term>Facteur nécrose tumorale</term><term>Récepteur biologique</term><term>Microglobuline β2</term><term>Homme</term><term>Afrique Ouest</term><term>Études transversales</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to identify immune markers that are independently associated with HIV infection or TB in vivo. Using commercially available assays, we measured concentrations of five immune markers in sera from 175 out-patients attending medical clinics in Cote D'lvoire and Ghana, West Africa. Patients were categorized into groups with TB only (TB<sup> </sup> HIV, n = 55), TB and HIV coinfection (TB<sup>+</sup> HIV<sup>+</sup>, n = 50), HIV infection only (TB HIV<sup>+</sup>, n = 35), or neither infection (TB HIV, n = 35). TB<sup>H</sup>IV<sup>+</sup> and TB HIV<sup>+</sup> groups were matched for blood CD4<sup>+</sup> lymphocyte count. Mean ± s.d. concentrations of β<sub>2</sub>-microglobulin were similarly increased in both the TB HIV<sup>+</sup> (5.3 ± 2.1 μg/ml, P < 0.001) and the TB <sup>+</sup>HIV<sup>+</sup> (5.0 ± 1.5 μg/ml, P < 0.0001) groups compared with the TB HIV group (2.2 ± 1.8 μg/ml), but were only slightly increased in the TB<sup>+</sup>HIV group (3.2 ± 1.8 μg/ml, P = 0.01), In contrast, mean serum concentrations of soluble tumour necrosis factor receptor type I (sTNF-RI) were similarly elevated in the TB HIV (1873 ± 799 pg/ml, P < 0.0001) and TB<sup>+</sup>HIV<sup>+</sup> (1797 ± 571 pg/ml, P < 0.0001) groups compared with uninfected subjects (906 ± 613 pg/ml), but there was only a small increase in sTNF-RI in the TB HIV<sup>+</sup> group (1231 ± 165 pg/ml, P = 0.03). Both TB and HIV infection were associated with substantial elevation of serum concentrations of soluble CD8, soluble CD54, and sTNF-R type II. Analysis of additional samples from groups of TB <sup>+</sup>HIV and TB <sup>+</sup> HIV <sup>+</sup> patients receiving anti-TB treatment showed significant and equal reductions in mean serum sTNF-RI concentrations, but no significant change in mean β<sub>2</sub>-microglobulin. Thus, serum β<sub>2</sub>-microglobulin and sTNF-RI serve as relatively independent markers of HIV infection and TB, respectively, in studies of co-infected persons.</div></front></TEI><affiliations><list><country><li>Côte d'Ivoire</li><li>États-Unis</li></country><region><li>Géorgie (États-Unis)</li></region></list><tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Lawn, S D" sort="Lawn, S D" uniqKey="Lawn S" first="S. D." last="Lawn">S. D. Lawn</name></region><name sortKey="Lal, R B" sort="Lal, R B" uniqKey="Lal R" first="R. B." last="Lal">R. B. Lal</name><name sortKey="Rudolph, D" sort="Rudolph, D" uniqKey="Rudolph D" first="D." last="Rudolph">D. Rudolph</name></country><country name="Côte d'Ivoire"><noRegion><name sortKey="Wiktor, S" sort="Wiktor, S" uniqKey="Wiktor S" first="S." last="Wiktor">S. Wiktor</name></noRegion><name sortKey="Ackah, A" sort="Ackah, A" uniqKey="Ackah A" first="A." last="Ackah">A. Ackah</name><name sortKey="Coulibaly, D" sort="Coulibaly, D" uniqKey="Coulibaly D" first="D." last="Coulibaly">D. Coulibaly</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001172 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001172 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:00-0517421
|texte= Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and β2-microglobulin, respectively
}}
| This area was generated with Dilib version V0.6.31. |  |